C. Atkins

发表

Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development.

A. Hassell, R. Gampe, J. Axten, 2013, ACS medicinal chemistry letters.

Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent inhibitors of the IGF-1R receptor tyrosine kinase.

L. Shewchuk, P. Sabbatini, A. Hassell, 2009, Bioorganic & medicinal chemistry letters.

Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).

Brian J. Wilson, L. Shewchuk, P. Sabbatini, 2009, Bioorganic & medicinal chemistry letters.

Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity.

L. Shewchuk, P. Sabbatini, A. Hassell, 2009, Bioorganic & medicinal chemistry letters.

In Vivo Cardiac Electrophysiologic Effects of a Novel Diphenylphosphine Oxide IKur Blocker, (2-Isopropyl-5-methylcyclohexyl) Diphenylphosphine Oxide, in Rat and Nonhuman Primate

C. Regan, C. Atkins, J. Lynch, 2006, Journal of Pharmacology and Experimental Therapeutics.

In vitro and in vivo induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitor

J. Luengo, Mark Cockerill, D. Mcnulty, 2020, Haematologica.

Cloning and expression of rat coagulation factor VII.

G. Feuerstein, C. Atkins, K. Murphy, 2003, Thrombosis research.

Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK).

L. Shewchuk, S. Rabindran, A. Hassell, 2012, Journal of medicinal chemistry.

GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers

P. Sabbatini, R. Kruger, Rakesh Kumar, 2009, Molecular Cancer Therapeutics.

Antitumor Activity of GSK1904529A, a Small-molecule Inhibitor of the Insulin-like Growth Factor-I Receptor Tyrosine Kinase

P. Sabbatini, Rakesh Kumar, S. Rabindran, 2009, Clinical Cancer Research.

Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity.

Brent M. Sanders, H. Alsaid, Rakesh Kumar, 2013, Cancer research.

GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers

P. Sabbatini, R. Kruger, S. Rabindran, 2009, Molecular Cancer Therapeutics.

Antitumor Activity of GSK1904529A, a Small-molecule Inhibitor of the Insulin-like Growth Factor-I Receptor Tyrosine Kinase

Brian J. Wilson, P. Sabbatini, S. Rabindran, 2009, Clinical Cancer Research.